Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IDMI and DORB both falling more than 29% now.
>MIVT has acquired two major subsidiaries, including Biosync Scientific in India and SagaX in Israel<
Anyone knows if SagaX device is better than other intra-aortic filters?
Circadin® (Prolonged-Release Melatonin) For Primary Insomnia Recommended For Approval In The EU
http://www.medicalnewstoday.com/medicalnews.php?newsid=69195&nfid=crss
Main Category: Sleep / Sleep Disorders / Insomnia News
Article Date: 27 Apr 2007 - 9:00 PDT
Neurim Pharmaceuticals Ltd today announced that the Committee for Medicinal Products in Human use (CHMP) of the European Medicines Agency (EMEA) has issued an approval recommendation for Circadin 2 mg (prolonged-release melatonin) as monotherapy for the short-term treatment of Primary Insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
The marketing authorisation application for Circadin was submitted by Neurim Pharmaceuticals to EMEA on October 2005. The adoption of a positive recommendation is the last step in the European regulatory approval process prior to the granting of marketing authorisation by the European Commission. Neurim anticipates that the Commission will ratify the CHMP opinion and issue marketing authorisation in the third quarter of 2007. If granted, the EU marketing authorisation will be valid in all 27-member states of the European Union.
"We are extremely pleased to have received the Committee's positive recommendation, which is a significant step towards Circadin becoming an important new treatment option in the EU for patients aged 55 or over suffering from Primary Insomnia," said Prof. Nava Zisapel, CSO of Neurim "Circadin was found effective in improving quality of sleep and sleep latency while also improving morning alertness and quality of life. At the same time Circadin does not impair vigilance, driving performance and memory and has no discernible withdrawal symptoms. These are considered to be of special importance in patients aged 55 years and over who suffer from Primary Insomnia"
Neurim Pharmaceuticals will launch, market and distribute Circadin through strategic alliances with reputable marketing and distribution partners. Neurim is actively seeking strategic alliances for the major European markets.
About Circadin
Circadin is a prolonged-release melatonin formulation. Melatonin is a naturally occurring hormone produced by the pineal gland and is structurally related to serotonin. Melatonin has a pivotal role in the regulation of circadian rhythms and sleep. The activity of melatonin at the MT1 MT2 and MT3 receptors is believed to contribute to its sleep-promoting and phase- resetting properties.
Endogenous melatonin levels decrease with age and may contribute to the common complaint of poor sleep quality seen amongst the middle aged and elderly. Administration of Circadin which essentially mimics the nocturnal melatonin profile, improve sleep quality and morning alertness and facilitates sleep onset in patients aged 55 or over.
About Primary Insomnia
Insomnia is a subjective complaint encompassing delay in onset, insufficient duration and/or poor quality of sleep. Not all three symptoms need to be present for the diagnosis of insomnia. Importantly, most insomniac people feel tired or distressed during the day.
The primary sleep disturbance is not associated with another medical disorder such as major depression and not due to the effects of a substance, for example caffeine, or a general medical condition, for example arthritis leading to pain. Insomnia is an extremely common condition with an overall prevalence of 27% (range 8% to 43%) among primary care attendees. The prevalence of sleep problems rises from about 15% in 20-54 year olds, to 30% in the over-55 year olds. Women are 1.5 times more likely than men to have this sleep disorder. Insomnia is associated with negative consequences for health-related quality of life, daytime well-being and has economic implications.
About Neurim
Neurim Pharmaceuticals Ltd. (1991) headquartered in Israel with a business development unit in Switzerland, is a drug discovery and development company founded in 1991. Neurim is focused on age-related disorders, primarily in the central nervous system (CNS). The main goal is to improve the quality of life in the older patient population. Circadin is the Company's first product reaching marketing approval. Other products are at various stages of preclinical and clinical development.
www.Neurim.com
>It’s about time. Colonoscopy is about as high-tech as a horse-drawn carriage.<
So are Liver biopsies and i have read in post #45822 at Biotach value board:
>This tool could presumably be used to balance trial arms in randomized, controlled studies of HCV therapies<
I found this
http://www.israel21c.org/bin/en.jsp?enZone=Health&enDisplay=view&enPage=BlankPage&enDisp....
about the BreathID diagnostic and disease management device which could serve for the same purpose.
This is their homepage:
http://www.breathid.com/index.htm
and if memory serves, their CEO said that one big pharma is already using the device in their clinical trials for liver disease drug.
LIFC - Don't you think that decellularized human skin product, collected from cadavers, will be replaced in the future (3-5 years) with recombinant products driven from animals or plants?
>the company's management will eventually be replaced at some point, won't it?<
Amen.
Notes from Compugene's presentation:
What can I say? so much promise, so little outcome...
Alex Kotzer (CEO for nearly 2 years) and Nurit benjamini (CFO) both sounded intelligent and reliable. I think they understood that selling their software or doing screening jobs for others are not enough. When I asked if they can show a prove to their long term efforts, Dr. Kotzer said that he can not but that there is a possibility that some of their customers used their software and data base and actually developed a drug but they will never know. The current business model is to try to move to clinical trials as soon as possible either with one of their own molecules or with a partnered one. The partner will define the target and will pay for milestones and royalties in case of a drug.
The company has laboratories with some 10-15 people doing in vitro and in vivo studies of proteins discovered by their computerized models. They also do some projects of discovering molecules for partners (Biosite, TEVA and MEDX). These are the kind of deals they are seeking in the future and I say, the more the merrier.
They are burning as much as $14M per year so they will be out of cash by the end of 2008 so I don't think that there is any point in buying the stock before that.
Court Stops Sandoz From Selling Generic Of Abbott's Antibiotic
[Good news for TEVA - Sandoz is out from the generic Biaxin market which is about $250M]
http://biotech.seekingalpha.com/article/32912?source=d_email&u=6464
Posted on Apr 20th, 2007 with stocks: ABT
Aaron F. Barkoff submits: This past Monday, Judge David H. Coar of the U.S. District Court for the Northern District of Illinois granted Abbott's (ABT) motion for a preliminary injunction to stop Sandoz [a Novartis Pharmaceuticals (NVS) subsidiary] from selling a generic version of Biaxin XL (clarithromycin extended release tablets).
Abbott earns about $300 million each year in the U.S. from sales of Biaxin XL, an antibiotic used primarily for the treatment of bacterial infections of the skin and upper respiratory system.
The preliminary injunction against Sandoz is a reversal of fortune for Abbott, considering that last December Judge Coar denied Abbott's motion for a temporary restraining order. Now, in a 61-page opinion (pdf file), Judge Coar explained that "after having the benefit of a full hearing, this Court is able to better decide the merits of enjoining Sandoz from further selling or marketing its extended release formulation of clarithromycin."
Abbott alleged that Sandoz's generic version of Biaxin XL infringes U.S. Patent Nos. 6,010,718 and 6,551,616, which claim extended release formulations of clarithromycin. Judge Coar found that Abbott demonstrated "a substantial likelihood of proving Sandoz's product infringes upon claims 1 and 4 of the '718 patent." Moreover, he found that Sandoz's obviousness and inequitable conduct defenses lack substantial merit.
With regard to inequitable conduct, Judge Coar wrote that although Sandoz showed a substantial likelihood of proving materiality and intent to deceive with respect to the '616 patent, Abbott abandoned the '616 patent claim in question on its own volition and "it seems wholly inequitable to hold a patent invalid for fraudulent conduct in the prosecution of a claim that was withdrawn before actual prosecution had even begun." Judge Coar further observed that "[r]edemption is one of the core principles of the American ethos."
Besides Sandoz, Abbott is fending off generic competition to Biaxin XL from Andrx, Ranbaxy, Roxane, and Teva (TEVA). In January, the Federal Circuit affirmed a preliminary injunction against Andrx. Last August, Abbott and Teva settled their litigation, although on Tuesday Teva filed a complaint (pdf file) in the Southern District of New York to enforce the settlement.
Nexavar is not yet approved for Hepatocarcinoma but shows promising results and is already being used by physicians I know off label for that indication.
http://www.medicalnewstoday.com/medicalnews.php?newsid=62848
So this is the reason for Biocell's run up this week. As usual this stock reacts days before the news are out.
"Why did Lifewave stock rise 900% in 4 months? "
Usually the answer reveals itself after the crash...
CGEN's board is not very much alive and Until recently i wasn't sure about the company either.
I will be attending their presentation on Sunday, April 22nd.
Any questions to be asked there anybody?
genisi
Price seems to move up again towards the 52 weeks height.
With earnings next week and those headlines saying- "Q1 loss grows", I'm expecting the to price again.
If Dr. Zeuzem is indeed objective, this CC sounds quite relaxing to VRTX investors.
Vertex - CIBC (they have target price of $42)
Highlights from Conference Call with Dr. Zeuzem on EASL Data
On 4/16, we hosted a conference call with Dr. Stefan Zeuzem, Chief of the Dept. of Medicine at the J.W. Goethe University Hospital, and an HCV trial investigator.
Dr. Zeuzem said that in the 12-wk telaprevir/Peg-IFN/RBV group, all 4 pts who did not meet the RVR requirement to remain in the arm still had robust antiviral responses, with viral loads <30 IU/mL at 4 wks. He believes these pts would have had similar SVR20 rates to pts who stopped at 12 wks.
Dr. Zeuzem believes an additional 12 wks of Peg-IFN/RBV, as in the "12+12" treatment arm, could potentially reduce the relapse rate by half. He said the rash associated with telaprevir was manageable, and mild to moderate in most pts, with only rare cases of severe rash (5-6% incidence).
Our conversation with Dr. Zeuzem confirmed our view that telaprevir produces rapid viral suppression in the majority of pts, with a side effect profile that will likely be acceptable in real-world practice. We continue to believe VRTX is undervalued, based on telaprevir's $2B+ market potential.
Data Published in Neurology
Teva: higher Copaxone dose showed increased efficiency
By Simon Kennedy
Last Update: 6:18 AM ET Apr 17, 2007
LONDON (MarketWatch) -- Teva Pharmaceutical Industries (TEVA)
said Tuesday that a Phase II study of multiple sclerosis drug Copaxone showed that patients receiving a 40 mg dose showed a 38% greater reduction in inflammatory disease activity than patients receiving a 20 mg dose. A Phase III study is expected to be concluded in May, with the results expected to be submitted to the U.S. Food and Drug Administration in 2008.
Vertex Hep-C Drug Shows Promise
By Adam Feuerstein
Senior Writer
http://www.thestreet.com/_yahoo/newsanalysis/biotech/10350400.html?cm_ven=YAHOO&cm_cat=FREE&...
4/15/2007 One of the big knocks against Vertex Pharmaceuticals (VRTX) has been that the data surrounding its hepatitis C drug telaprevir was a bit thin compared with the hype and expectations enveloping it.
But the divide between hype and reality is definitely starting to narrow, especially after Saturday, when researchers presented new clinical data on telaprevir that shows the drug having a profound, and positive, effect in the treatment of hepatitis C.
Vertex shares closed Friday down $1.39, or 4%, to $30.16.
There is still a lot unknown about telaprevir and what its ultimate role in hepatitis C treatment will be, but the weight of evidence is growing to suggest that the drug, at the very least, might cut in half the treatment duration for hepatitis C patients. It might also increase the number of patients cured of the disease.
If one or both of those things happens, telaprevir could be the billion-dollar molecule that Vertex CEO Joshua Boger has long searched for.
Telaprevir is a pill designed to attack hepatitis C by inhibiting the protease enzyme, one of the key enzymes the virus uses to copy itself. This "direct antiviral" approach differs from current hepatitis C drugs, which boost the immune system's ability to tamp down and eliminate the virus.
The current standard of care for hepatitis C patients is a weekly injection of long-acting alpha interferon combined with daily oral doses of a generic drug, ribavirin. A normal treatment course for Type 1 hepatitis C (the most prevalent form) takes 48 weeks to complete. But the standard treatment cures only about half of patients, and many patients find the side effects, such as flu-like symptoms, anemia and depression, difficult to tolerate.
Promising Results
The Vertex phase II studies underway are testing to see whether telaprevir plus various combinations of interferon and ribavirin (the standard treatment) can increase cure rates and/or shorten the duration of treatment. Researchers presented interim results from one of these studies, dubbed PROVE 1, at a European liver disease meeting held in Barcelona.
Of the 175 hepatitis C patients receiving telaprevir plus standard therapy in the PROVE 1 study, 79% reported having undetectable levels of virus in their bloodstream four weeks into treatment. By comparison, 11% of the 75 patients receiving placebo plus standard therapy reported having an undetectable viral load.
Beating back the hepatitis C virus to undetectable levels after just four weeks of treatment is what is known as a "rapid virologic response," or RVR. Previous studies of standard therapy alone have shown that patients who achieve an RVR can be treated for shorter periods of time (24 weeks instead of 48) and are more likely to become cured of hepatitis C.
Side Effects
Telaprevir's ability to greatly increase the percentage of patients who achieve RVR bodes well for the experimental drug. But this efficacy may not come without costs. Through 12 weeks of treatment, 11% of telaprevir patients discontinued the study, vs. 3% of patients in the placebo arm. The most common reason for telaprevir patients to stop using the drug was rash, reported by seven patients. Patients also reported gastrointestinal problems and anemia.
While doctors at the Barcelona meeting said the telaprevir rash was manageable and treatable, anecdotal patient reports have suggested the rash is severe and a significant obstacle to completing treatment.
Michael Partridge, a Vertex spokesman, says the overall dropout rate so far in the Prove 1 study was relatively low. He said the rash reported may not be distinguishable from rash often reported in patients taking ribavirin but added that the company and its researchers continue to monitor it.
As I discussed in a previous column, many investors were anxiously awaiting the results of a particular arm (Arm D) of the PROVE 1 study that gave patients telaprevir plus standard therapy for a relatively short 12 weeks. Researchers then stopped treatment for these patients altogether but followed them to determine what happened to the hepatitis C virus in their systems.
As reported Saturday, 17 patients were enrolled in Arm D, but only nine of them made it through all 12 weeks of treatment. Of these nine, six had undetectable levels of virus measured 20 weeks after treatment stopped.
A 66% "cure" rate at 20 weeks is good, but the small number of patients makes the result difficult to interpret. Furthermore, the high number of patients who either discontinued treatment or relapsed after treatment raises questions about the viability of treating patients with only 12 weeks of telaprevir and standard of care.
It's likely that investors will view the Arm D results as somewhat of a disappointment.
Vertex's Partridge says Arm D is a proof of concept and that more data is necessary before passing judgment. A European version of PROVE 1 -- dubbed PROVE 2 -- is enrolling more patients and will provide a more definitive answer.
As I said above, exactly how long patients will require treatment is one of the unknowns about telaprevir. Additional data to be presented later this year from PROVE 1 and PROVE 2 should clarify this.
As it stands, however, Vertex believes that telaprevir will be dosed for 12 weeks, with standard of care (interferon plus ribavirin) dosing likely to last 12 to 24 weeks. (At its longest, that's 12 weeks of triple combination plus another 12 weeks of standard therapy.) Recall that current standard treatment calls for interferon and ribavirin to be dosed for 48 weeks.
The benefit shown by telaprevir does continue past four weeks, according to additional data presented Saturday.
After 12 weeks of treatment, 70% of telaprevir patients reported undetectable levels of virus compared to 39% of patients in the placebo arm.
No sweat Spartex, I was just doing the good old cut&paste trick from Brian Abrahams, M.D., CIBC Biotech Analyst who covered the conference, so the credit is his.
genisi
I know Proneuron quite well. I do not believe anything they say or claim. The studies are always biased. Proneuron is bankrupt and the lawsuit is probably an excuse to extort some money from Teva and to provide explanations to their investors for their failure.
At the current price, I bet that some insiders will start selling as soon as they are able to (that should not be long), that also can drive the stock down to earth.
I am aware of the buzz, I heard expressions like "The next Genzyme" and I think that Frost and management honestly believe it is doable.
BTW, average vol did increase since the end of March, can hardly call it decent but perhaps a trend.
I will probably be able to post this if anyone is interested:
http://conferences.cibcwm.com/hour/ViewCall.aspx?CONF_CALL_ID=70
Update from CIBC Biotechnology & Specialty Pharma Conference
Provided more details on ph2/3 fibroid study, which showed that patients on Proellex had similar scores on UFS-002 "symptom severity" and "concern" scales to historical disease-free patients.
Following meeting with FDA last month, plan to pursue chronic treatment with 4-month dosing followed by drug holiday to allow menstruation.
Reported additional interim data from ongoing ph.IIa endometriosis study, which showed 95% pain-free days for women on the 50mg dose (vs. 70-75% for women on Lupron).
Plan Androxal partnership in near term, hinted that it would be more likely global (vs. ex-US. only).
Bottom Line: Based on Proellex's clinical profile and market potential, we believe RPRX is undervalued on a risk/reward basis.
CIBC Conference: Highlights From the Diabetes and Obesity Panel
Panel participants included Dr. Jay Skyler (University of Miami), Dr. F. Xavier Pi-Sunyer (Columbia University), and Dr. Stephen Richardson (NYU).
The panelists had mixed views of inhaled insulin. Dr. Skyler liked the inhaled route and indicated that Exubera's slow uptake could be partly due to poor promotion. Dr. Pi-Sunyer was less enthusiastic, citing complications such as different dosages vs injectables and cumbersome delivery methods.
Dr. Pi-Sunyer believed that lorcaserin was relatively unlikely to cause CV side effects based on the drug's specificity for the 5HT-2c receptor and somewhat narrow therapeutic window, defined by activity at the 5HT-2a receptor. Furthermore, he was unconcerned about pro-seizure potential.
The panel agreed that Byetta had an attractive profile for use in early diabetes management. All felt that the drug's weight loss effects more than compensated for its injection schedule. Importantly, the panelists agreed that needle size would not limit adoption of Byetta LAR.
A recent example regarding PDLI's CEO taken from Third Point's letter:
>There is no better example of McDade’s “empire building” philosophy, pathological selfishness and poor business judgment than his decision to build out PDLI’s absurdly large and unnecessary new corporate headquarters (the “Taj Mahal”). It is appalling that Mr. McDade is spending nearly $100 million of our money to build out 450,000 square feet of leased space, much of which is completely unnecessary.>
http://www.sec.gov/Archives/edgar/data/882104/000119312507078826/dex991.htm
VRTX-
Thanks Jon for the insight.
I think that most VRTX investors expect a higher rate than the 40-50% range Piper Jaffray analyst predicts.
VRTX- " Piper Jaffray analyst Rachel McMinn wrote in a research note. "We view an SVR rate in the 40 percent to 50 percent range as more probable."
That's a lot lower than IDIX's board predictions:
http://www.investorshub.com/boards/read_msg.asp?message_id=15613926
I'm posting this one here rather than in TEVA's board since the main issue of this article is PLX.
The one that got away from Teva
10.4.07 | 13:28 By Yoram Gavison
http://www.haaretz.com/hasen/pages/ArticleContent.jhtml?itemNo=846962
The business development managers at Teva (TASE, Nasdaq: TEVA) have been working overtime ahead of the last leg in the race to buy Merck's generic drugs unit, which will cost as much as $6 billion. If Teva closes the deal, it will be the second-biggest in its history, after the January 2006 acquisition of Ivax Corp for nearly $8 billion.
The ruckus about Merck has among other things distracted attention from the one that got away.
In September 2006, Teva entered an agreement to co-develop two drugs based on technology developed by Protalix. Teva was to get exclusive marketing rights and Protalix was to get royalties on sales. But if the development flopped, then Teva's investment would simply be written off.
Protalix had developed an advanced technology to engineer plant cells by inserting human genes. The mutated plant cells would then make human protein coded by the genes, for use in drugs. The technology could be a gold-mine, especially given that patents protecting $100 billion worth drugs of biological origin expire by 2010.
Also, Protalix is close to the final testing stage of a drug to treat hereditary gout.
Unhappily for Teva's investors, the Israeli drug company did not invest in Protalix, but two of its top executives did, personally. Shortly before signing the agreement in Teva's name, chairman Eli Hurvitz and his deputy Philip Frost privately invested not-small amounts in the startup.
The Pontifax fund, which Hurvitz leads, invested $1.5 million in Protalix back in March 2005. As of the end of 2006, Pontifax owned 8.2% of Protalix.
Frost for his part heads an investment group that injected $16 million for 15% of Protalix's shares. The group also has an option to buy 5% more for $5.3 million.
Not content with that, Frost initiated a reverse merger, in which Protalix merged with a Wall Street-listed company he controlled.
If Teva had bought the Protalix shares itself, instead of its executives, it evidently wouldn't have been sorry. At the end of 2006, Frost owned Protalix shares worth $277 million, which is a handsome return on his investment of $21 million. Pontifax's shares in the biodrugs company is worth $158 million, and all it invested was $1.5 million.
>I don't know if most VRTX investors would look at it that way<
If VRTX investors indeed expect a higher than 70% rate, the stock might go back to mid $20 soon.
ITMN-CIBC note
Highlights from Conference Call with Dr. Raghu on Idiopathic Pulmonary Fibrosis
On 4/5, CIBC hosted a conference call with Dr. Ganesh Raghu, chief of the Chest Clinic at the University of Washington Medical Center and expert in IPF.
Dr. Raghu was encouraged by the ph.III pirfenidone results in IPF presented by Shionogi. He believes the VC endpoint used in Shionogi's study should correlate well with the FVC endpoint in ITMN's CAPACITY study, and that FVC/VC are the most valid surrogate measures for response to treatment.
Dr. Raghu believes the full data set for Shionogi's ph.III study, particularly side effects, dropout rates, and secondary endpoints such as exacerbations, will provide a clearer picture as to pirfenidone's potential. He does not see any continuing role for Actimmune in IPF, given the recent negative data.
Overall, our conversation with Dr. Raghu supported our view that pirfenidone is a promising therapy for IPF, a significant unmet need. We continue to believe ITMN shares are attractive at current levels, and expect antiviral efficacy data for ITMN-191 in HCV will drive shares higher in 2H07.
CIBC is bullish on ITMN. They cover the company with Stock Rating: Sector Outperformer.
This is from a March 22, 2007 report:
Given the solid Shionogi data, we believe there will be additional upside in ITMN today. Based on our continued confidence in pirfenidone's probability of success, and the likelihood of positive antiviral data for ITMN-191 in HCV in 2H07, we believe ITMN shares remain attractive.
Important Disclosure Footnotes for InterMune, Inc. (ITMN)
1 CIBC World Markets Corp. makes a market in the securities of InterMune, Inc.
CIBC CC on Pulmonary Fibrosis
>I don't have any business with them<
Me neither but I can get their research reports.
I have no further info, will post in case something will turn up.
This is the link but there is nothing in it beyond what I have already posted.
http://conferences.cibcwm.com/hour/ViewCall.aspx?CONF_CALL_ID=68
CIBA one more-
CIBC To Host Conference Call:
Successes and Failures in Finding a Treatment for
Pulmonary Fibrosis
On Thursday, April 5, at 11 a.m. ET (8 a.m. PT), we will host a conference call with Dr. Ganesh Raghu, chief of the Chest Clinic at the University of Washington Medical Center and a well-known authority in idiopathic pulmonary fibrosis (IPF). Dr. Raghu will discuss his interpretation of the phase III pirfenidone data recently presented by Shionogi, and the implications for InterMune's phase III pirfenidone program. He will also give his thoughts on the potential role of pirfenidone in the future treatment of IPF. Dr. Raghu will review the current therapeutic approaches used in patients with IPF, and how the recent negative data for InterMune's Actimmune is likely to change such practices. He will also provide an overview of other agents currently in development to treat IPF. A Q&A session will follow.
>market cap ought to be in the $200-400M range.<
We are in agreement. My estimation is $300M and my hope is $600M.
Praveen I wish this market cap will hold when real trading will start with the stock because I bought Biocell at 1700NIS, it is now 4500NIS reflecting MC of only $250M for PLX so my money will multiply...
...but I don't think so. I look at this 2.056B$ as a theoretical number only. With the current tiny vol of trade the MC has no meaning.
For now, holders of the 10% stocks that can be traded hardly made a move. I think that PLX will issue soon more stocks and than we'll see real action and evaluation.
Most of us agree (including off record talk with people who work for PLX) that the current market cap is way to hight. It become this hight simply because there is no real trade with the stock yet. My guess is that PLX will first announce the beginning of phase III and some time after that they will issue more shares. As soon as they do that, we'll know the real MC.
Amicus- This is their 2nd time. In August 2006, due to market conditions, the Company withdrew its IPO. At least for the AT2101 molecule (treatment for Gaucher disease), they will compete with PLX too.
Quark Biotech known as QBI, files for IPO at Nasdaq. CEO Daniel Zurr said last month they want to raise $70 at a value of $300.
Quark Biotech, which develops RNA interference-based therapeutics for the treatment of diseases associated with oxidative stress, filed for IPO Friday. JPMorgan and Banc of America are bookrunning the deal. Terms have not yet been announced.
http://www.ipohome.com/common/ipoprofile.asp?ticker=QURK
>At one moment "RED" numbers came 11 times out of 12 spins.<
Perhaps the dice was loaded...
You got me on this one. For the record, I only know this from reading, not investing.
Idit